Nestlé Sells Its Mass-Market Vitamins for $1 Billion—and the Multiple Tells the Whole Story
Nestlé agreed on September 1 to sell seven vitamin, mineral and supplement brands—Nature's Bounty, Osteo Bi-Flex, Puritan's Pride, Nuun and three others—plus its U.S. private-label supplements operation to Yellow Wood Partners for $1.0 billion. The deal covers roughly $1.2 billion in 2025 revenue and is expected to close in H1 2027. Nestlé shares closed at CHF 78.51, off 0.39%, pricing this as portfolio cleanup under CEO Philipp Navratil.
The retained brands matter more than the divested ones. Nestlé is keeping Solgar, Pure Encapsulations and Garden of Life—science-oriented properties that management has repeatedly singled out for strong growth.
The Multiple Compression
In 2021, Nestlé paid $5.75 billion for the broader Bountiful Company portfolio at 16.8× EBITDA. The assets now being sold generated an estimated $150–160 million of EBITDA in recent deal-room commentary. At $1.0 billion, Yellow Wood enters near 6.3–6.7×—roughly 60% below the multiple Nestlé paid for a larger package that included the premium brands it is keeping.
The two deals are not apples-to-apples, so headline writedown math overstates the destruction. The directional signal is hard to miss: market pricing for undifferentiated vitamin brands has collapsed.
A comparison sharpens the picture:
| Deal | Multiple | Sales multiple |
|---|---|---|
| P&G / Thorne (Aug 2026) | ~$3.8B for ~$650M revenue | ~5.8× sales |
| Nestlé / Yellow Wood (Sep 2026) | $1.0B for $1.2B revenue | ~0.83× sales |
On a revenue-multiple basis, the spread between a science-backed, practitioner-trusted supplement brand and a mass-market pill line is now roughly 7 to 1.
GLP-1 Is Adding Supplement Customers
The lazy read—GLP-1 drugs kill the supplement industry—collides with actual spending data.
PwC June UK survey:
| GLP-1 user behavior | % |
|---|---|
| Spending more on vitamins/supplements | 40% |
| Spending more on high-protein foods | 54% |
U.S. survey data: active GLP-1 users report spending increases of roughly:
| Category | Increase |
|---|---|
| Protein supplements | ~24% |
| Fiber | ~22% |
| Collagen | ~20% |
| Multivitamins | ~18% |
PwC's May 2026 U.S. data now show 21% of households containing a current GLP-1 user, up from 9% in January 2025. Grocery spending per GLP-1 household falls about 5.5%—fewer calories consumed, heavier nutritional burden per calorie.
Nestlé's own results confirm the segmentation:
- Q2 2026 Nutrition organic growth recovered to +1.7%, with adult and medical nutrition strong, powered by Vital Proteins and Pure Encapsulations
- The Vitamin Shoppe reports fiber sales up 20% YTD, fiber searches up 59%, psyllium-husk searches up 150%
Euromonitor global consumer-health market (2025):
| Segment | Size / Growth |
|---|---|
| Total market | ~$338 billion, growing ~4% |
| Sports nutrition | Growing ~9% |
| Conventional weight-management supplements (fat burners, appetite suppressants, diet pills) | ~1% growth (identifiable GLP-1 casualty) |
The Pill Lost Its Moat
This is where the divestiture becomes a case study. The economics of a generic multivitamin have deteriorated from two directions at once:
1. Private-label pressure:
| Metric | Value |
|---|---|
| U.S. private-label sales (2025) | Record $282.8 billion, growing 3.3% |
| National brand growth | 1.2% |
| Private-label unit share (H1 2026) | 23.8% |
When a retailer prints "Vitamin D3 2,000 IU" on its own bottle, the branded equivalent struggles to defend premium pricing.
2. GLP-1 spending migration: users are moving spend toward condition-specific products—protein for muscle preservation, fiber for GI side effects, electrolytes for hydration on reduced intake, collagen for hair and skin changes during rapid weight loss. These purchases carry higher intent and higher willingness to pay than an annual Costco multivitamin restock.
Nestlé is engineering around exactly this demand:
- Two weeks before the divestiture, its CTO called GLP-1 a "huge opportunity"
- Launched Boost Advanced Nutrition Shake with 35 grams of protein
- Expanded collagen applications through Vital Proteins
- Patented nutrient combinations for post-GLP-1 consumers
The industry is no longer rewarding the pill. It is rewarding the clinical reason a consumer believes a specific formulation is worth paying for. Generic prevention—a vague promise of wellness bottled in commodity ingredients—is getting squeezed between private label below and science-backed brands above. GLP-1 adoption accelerates that squeeze by converting millions of consumers from casual supplement buyers into patients with specific, identifiable nutritional deficits. A $1 billion divestiture at 6.5× EBITDA is what that conversion looks like on a term sheet.
Not investment advice.